other material
confidence high
sentiment positive
materiality 0.70
MyMD Pharmaceuticals announces positive preclinical data for MYMD-1 in RA model
Q/C TECHNOLOGIES, INC.
- MYMD-1 reduced histopathological changes vs placebo (p<0.0001 composite score) in RA model.
- Disease severity reduced 47% with MYMD-1 450 mg/kg/day orally vs 37% for etanercept.
- Oral TNF-α inhibitor shows potential to disrupt current market; early-stage RA trials planned.
- Data presented at 2023 Society of Toxicology Annual Meeting on March 20, 2023.